| scholarly article | Q13442814 |
| P2093 | author name string | Gyeong-Won Lee | |
| Je-Hwan Lee | |||
| Kyoo-Hyung Lee | |||
| Hawk Kim | |||
| Min Kyoung Kim | |||
| Myung Soo Hyun | |||
| Young-Don Joo | |||
| Jung-Hee Lee | |||
| Young Joo Min | |||
| Won-Sik Lee | |||
| Dae-Young Kim | |||
| Hun Mo Ryoo | |||
| Sung-Doo Kim | |||
| Jae-Hoo Park | |||
| Sung-Hwa Bae | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 701-709 | |
| P577 | publication date | 2012-11-05 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. | |
| P478 | volume | 31 |
| Q36157163 | A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial |
| Q45235834 | A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. |
| Q38777460 | Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. |
| Q48551157 | Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors |
| Q26824434 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities |
| Q35766718 | Allogeneic hematopoietic cell transplantation in septuagenarians |
| Q38199056 | Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it? |
| Q41200444 | Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission |
| Q36761819 | Blood Research: a new journey of passion with harmony beyond Asia onto the world |
| Q38604900 | Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis |
| Q40475236 | Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. |
| Q36608468 | Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu |
| Q36182610 | Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis |
| Q86643501 | Busulfan-based conditioning regimens: not all partners are equal |
| Q47144269 | Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy |
| Q58798385 | Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients |
| Q46788345 | Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of E |
| Q35647641 | Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. |
| Q39306717 | Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia |
| Q33917170 | Conditioning regimens for hematopoietic cell transplantation: one size does not fit all |
| Q37397003 | Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage. |
| Q36742108 | Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients |
| Q42175192 | Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies |
| Q39632454 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. |
| Q88088400 | Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised |
| Q36715911 | Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial |
| Q47211374 | Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation |
| Q36157233 | Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. |
| Q34402494 | Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning |
| Q34544439 | Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). |
| Q40190932 | Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. |
| Q34807259 | Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration |
| Q58586521 | Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study |
| Q54179395 | Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? |
| Q36792818 | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| Q53346369 | Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. |
| Q37370651 | Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation |
| Q40129891 | Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT. |
| Q90372460 | Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS |
| Q38366632 | Reduced-intensity conditioned allogeneic SCT in adults with AML. |
| Q86766498 | Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) |
| Q87874816 | Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial |
| Q38441123 | Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. |
| Q89297777 | The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation |
| Q36703516 | Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. |
| Q49790702 | Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. |
| Q99202596 | Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by th |
| Q87417746 | Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS |
| Q37718826 | Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia |
| Q94589497 | [Effect of cyclophosphamide on hematopoietic stem cells in mice with iron overload] |
Search more.